Conviction
1 → 3
Conviction●●●○○3 of 5
Research target$2.05Snapshot target
Thesis statusINTACTLast reviewed 7/8/26
Market cap$522MSnapshot value
Research history
See all PACB changes ↗What changed
Target
— → $2.05
Thesis status
NEEDS_MORE_DATA → INTACT
Last reviewed
Not reviewed → 7/8/26
Target
— → $2.05
Long-read sequencing pure-play. HiFi (Revio, Vega desktop) answers a different question than Illumina (structural variants, full-length isoforms). BIOSECURE tailwind.
Vega desktop launch expanding addressable market; PureTarget for hard-to-call clinical regions; BIOSECURE reshoring; long-read clinical adoption (rare disease, oncology).
Unprofitable (~$522M market cap, negative EBITDA); Illumina + Roche squeezing from both sides; ONT competition in native long-read; slow clinical reimbursement pathway.
needs X/Reddit sentiment sweep
Snapshot · 7/8/26🟡 Mixed · ins-$1.4M · 13F 11+/13- · short↑0.23
Snapshot · 7/8/26